Biomarkers and Heart Failure
Aug 26, 2023
Biomarkers and Heart Failure
Hanna Gaggin, MD, MPH, clinical investigator and cardiologist in the Massachusetts General Hospital Heart Center, is passionate about helping patients with preserved ejection fraction and type 2 myocardial infarction, both of which are not well understood. So far, her research has looked at biomarkers in patients with preserved ejection fractions, which has made progress in finding treatment options. However, the prognosis for type 2 MI remains poor. Dr. Gaggin hopes to advance type 2 MI investigation to find treatment pathways in order to help these patients.https://advances.massgeneral.org/card … https://pages.connect.massgeneral.org …
Content
8.44 -> I think there are two really important topics
that I love, and I want to kind of spend the
13.59 -> rest of my life looking at what happens in
these patients.
16.59 -> Number one is patients with heart failure
with preserved ejection fraction.
21.14 -> Millions of people are affected by heart failure,
and yet 50% of the patients who are affected
26.09 -> with heart failure, those with preserved ejection
fraction, we just don't know anything about.
31.379 -> We are beginning to understand what is going
on and some of the progress we have made in
37.73 -> our research lab is looking at the biomarkers
in these patients with heart failure.
42.829 -> We're beginning to understand the pathophysiology
behind them, we're beginning to understand
47.64 -> what are some of the treatment options that
may suggest benefit to these patients, and
53.589 -> that's something I think we can really make
a lot of progress on.
56.39 -> The other group that we are looking at is
patients with something called a type 2 MI
61.76 -> or type 2 myocardial infarction.
64.479 -> It's commonly called demand-supply mismatch
related myocardial infarction.
69.71 -> These are patients that we diagnosed them
as having MI but it's not because of narrowed
75.05 -> coronary artery disease or because of coronary
artery ischemia, but it's because of other
80.82 -> factors, external factors, that are affecting
them.
84.44 -> These patients have prognosis that's as bad
as people with type 1 MI, acute coronary syndrome,
92.04 -> or even worse than, but we don't have any
treatment options for them.
95.75 -> We don't even understand what is causing it,
what is the critical link that is leading
100.49 -> to these myocardial infarctions.
102.28 -> So we want to study these patients in the
CASABLANCA study with 1,251 patients undergoing
108.38 -> angiography, and we found that if you have
type 2 MI, then in the subsequent years you're
117.99 -> more likely to have major cardiovasicular
adverse events, all cause mortality, cardiovascular
124.77 -> mortality, or even heart failure, two to three
times more likely than those who did not.
130.78 -> And those are patients who I feel are so helpless
because we don't have anything to offer them,
136.66 -> and, I mean, I feel very helpless taking care
of these patients because they're really sick
142.14 -> and I know their prognosis is poor, but I
don't have any tools to offer them any medications,
147.97 -> any treatment pathways, and I want try to
find something in order to help them.
Source: https://www.youtube.com/watch?v=zwkS4Hqp4Rw
